MFN1 and Charcot-Marie-Tooth disease type 2A1: Given that CMT2A is caused by mutations in MFN2, not MFN1, we hypothesized that compounds capable of rescuing mitochondrial fragmentation in Mfn2 KO MEFs may have therapeutic potential for CMT2A patients.